A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, Kazuhiko Nakagawa, Mitchell Keegan et al.|Cancer Chemotherapy and Pharmacology|2016

Cited by 109